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THE PATENTABILITY OF THE CRISPR-CAS9 GENOME EDITING 
TOOL 
 
DEBORAH KU 
 
ABSTRACT 
 
The biotechnology sector is rapidly changing with the increase in 
technological advancements. 1  The laws governing patent protection, 
specifically the laws governing patent eligibility, have also changed to adapt 
to these innovations.2 This paper focuses on the CRISPR-Cas9 technology, 
a genome editing tool that is changing the field of genetic engineering.3 As 
of November 2016, the U.S. Patent and Trademark Office has issued 42 
patents on the CRISPR-Cas9 technology.4 This paper addresses the issue of 
whether patents claiming the core CRISPR-Cas9 technology can survive a 
35 U.S.C. §101 (“§101”) subject matter eligibility challenge. The paper 
concludes that the CRISPR-Cas9 technology is patentable subject matter 
under §101. In reaching this conclusion, the paper will do the following: 
explain the CRISPR-Cas9 technology, compare it to genome editing tools 
that utilize ZFNs and TALENs, examine relevant §101 Supreme Court and 
Federal Circuit decisions, introduce the current Alice framework, and apply 
it to a hypothetical §101 invalidity dispute. 
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I. CRISPR TECHNOLOGY: A PRECISE GENOME EDITING TOOL 
CRISPR, a genome editing technology, has been hailed as “the biggest 
biotech discovery of the century.”5  CRISPR is not the first or the only 
genome editing tool available to researchers.6 However, it has generated a 
substantial amount of excitement and concern among not only scientists, but 
those outside of the scientific community as well.7 CRISPR has been used in 
mice to treat sickle cell anemia, a debilitating blood disorder caused by a 
 
 5. Antonio Regalado, Who Owns the Biggest Biotech Discovery of the Century?, MIT TECH. 
REV. (Dec. 4, 2014), https://www.technologyreview.com/s/532796/who-owns-the-biggest-biotech-
discovery-of-the-century. 
 6. See Gene Editing, HORIZON, https://www.horizondiscovery.com/gene-editing (last visited Jan. 
20, 2017); Hyongbum Kim & Jin-Soo Kim, A Guide to Genome Engineering with Programmable 
Nucleases, 15 NAT. REV. GENET. 321 (2014). 
 7. See Bruce Booth, Riding the Gene Editing Wave: Reflections on CRISPR/Cas9’s Impressive 
Trajectory, FORBES (May 31, 2016), http://www.forbes.com/sites/brucebooth/2016/05/31/riding-the-
gene-editing-wave-reflections-on-crisprs-impressive-trajectory/#184c8697141c. 
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single nucleotide change (i.e. A to T) in the DNA. 8  CRISPR screening 
technologies have also been implemented to identify human host proteins 
that are vital to Zika and dengue viral replication.9 Even more, CRISPR was 
used on a human for the first time this year.10 Chinese scientists are currently 
conducting human trials with CRISPR on patients suffering from a specific 
form of lung cancer. 11  This genome editing tool is reshaping the way 
scientists conduct research, and is predicted to revolutionize not only the 
fields of medicine, biology, and agriculture, but much like cars, the way 
humans live.12 
A. The CRISPR-Cas9 System: A Closer Look 
CRISPR stands for Clustered Regularly Interspaced Short Palindromic 
Repeats, and is used to refer to the entire CRISPR/CRISPR-associated (Cas) 
system.13 The CRISPR-Cas9 system (hereinafter “CRISPR”), as previously 
mentioned, is a genome editing tool.14 In order to understand how CRISPR 
can be used to manipulate genes, it is necessary to understand the general 
overview of the central dogma of molecular biology.15 Each gene provides 
instructions for building a particular protein.16 This information is stored in 
the DNA. 17  Characteristics such as eye color, hair color, and physical 
features are all manifested through the proteins our bodies make. 18 
Therefore, a cell makes a particular protein from the information stored in 
 
 8. See generally Heidi Ledford, CRISPR Deployed to Combat Sickle-cell Anaemia, NATURE 
(Oct. 12, 2016), http://www.nature.com/news/crispr-deployed-to-combat-sickle-cell-anaemia-1.20782. 
 9. Jim Fessenden, Scientists Use CRISPR to Discover Zika and Dengue Weaknesses, PHYS.ORG 
(June 21, 2016), https://phys.org/news/2016-06-scientists-crispr-zika-dengue-weaknesses.html. 
 10. Timothy J. Seppala, China Completes First Human Trial with CRISPR-edited Genes, 
ENGADGET (Nov. 15, 2016), https://www.engadget.com/2016/11/15/china-completes-first-human-trial-
with-crispr-edited-genes/. 
 11. PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer, 
CLINICALTRIALS.GOV (Nov. 2016), https://clinicaltrials.gov/ct2/show/NCT02793856. 
 12. See Maywa Montenegro, CRISPR is Coming to Agriculture- with Big Implications for Food, 
Farmers, Consumers and Nature, ENSIA (Jan. 28, 2016), https://ensia.com/voices/crispr-is-coming-to-
agriculture-with-big-implications-for-food-farmers-consumers-and-nature/. 
 13. Martin Jinek et al., A Programmable Dual-RNA-guided DNA Endonuclease in Adaptive 
Bacterial Immunity, 337 SCI. 816 (2012). 
 14. Regalado, supra note 5. 
 15. See Central Dogma (DNA to RNA to Protein), KHANACADEMY, 
https://www.khanacademy.org/science/biology/gene-expression-central-dogma/ (last visited Dec. 23, 
2016). 
 16. See Intro to Gene Expression (Central Dogma), KHANACADEMY, 
https://www.khanacademy.org/science/biology/gene-expression-central-dogma/central-dogma-
transcription/a/intro-to-gene-expression-central-dogma (last visited Dec. 23, 2016). 
 17. Id. 
 18. Id. 
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our DNA through a process known as gene expression.19 The cell will find 
the appropriate gene and create a copy of the gene (i.e. the instruction set) 
through a process known as transcription.20 This copy is called messenger 
RNA (mRNA). mRNA is then read and “decoded” to build a protein through 
a process called translation.21 
CRISPR, in the simplest terms, can be described as an RNA-guided 
nuclease system. RNA, a chemical cousin of DNA, can recognize and bind 
to a matching DNA sequence.22 A nuclease is a type of enzyme that can cut 
DNA. 23  Therefore, CRISPR is a 2-part system that consists of a Cas9 
nuclease, which acts as a pair of “molecular scissors,”24 and a guide RNA 
(gRNA), which leads the Cas9 nuclease to the target DNA sequence.25 The 
gRNA, which consists of roughly 20 nucleotides (bases), can be 
programmed to match with specific sequences in the DNA.26 Researchers 
studying a specific genetic disorder can design a gRNA27 or simply order it 
online.28 
Once in the cell, the gRNA and Cas9 bind together to form a Cas9-
gRNA complex. 29  This Cas9-gRNA complex then searches through the 
entire genome to find the exact portion of the DNA that matches with the 20 
 
 19. Id. 
 20. Id. 
 21. Id. 
 22. Jekaterina Aleksejeva, RNA Facts—the Ultimate Guide to the Chemical Cousin of DNA, 
LEXOGEN (July 6, 2016), https://www.lexogen.com/rna-facts-the-ultimate-guide-to-the-chemical-
cousin-of-dna/. 
 23. CRISPR Systems in Prokaryotic Immunity, DOUDNA LAB (2012), 
http://rna.berkeley.edu/crispr.html (last visited Jan. 26, 2017); s). ee also Why is Everyone Talking 
About CRISPR-Cas9 Technology?, DNA-SCISSORS (June 6, 2016), https://dnascissors.wordpress.com; 
Peter Cavanagh & Anthony Garrity, The Answer, CRISPR/CAS9 BLOG, 
https://sites.tufts.edu/crispr/answer/ (last visited Jan. 26, 2017). 
 24. Guy Riddihough, CRISPR Cas9 Molecular Scissors, 351 SCI. 827, 827 (2016), 
http://science.sciencemag.org/content/351/6275/827.1; Ellen Jorgensen, What You Need to Know About 
CRISPR, TEDSUMMIT (Oct. 24, 2016), 
https://www.ted.com/talks/ellen_jorgensen_what_you_need_to_know_about_crispr. 
 25. Id. See also Cavanagh & Garrity, supra note 23. 
 26. Jorgensen, supra note 24; CRISPR Systems in Prokaryotic Immunity, supra note 23. 
 27. Kenian Chen et al., CRISPR Explorer: A Fast and Intuitive Tool for Designing Guide RNA for 
Genome Editing, 3 J. BIOLOGICAL METHODS e56 (2016). 
 28. John Doench, How to Design Your gRNA for CRISPR Genome Editing, ADDGENE (Feb. 16, 
2016), https://innovativegenomics.org/blog/how-to-make-a-guide-rna-for-cas9/. See Jacob Corn, How 
to Make a Guide RNA for a Cas9 Knockout, INNOVATIVE GENOMICS INITIATIVE (Aug. 12, 2014), 
https://innovativegenomics.org/blog/how-to-make-a-guide-rna-for-cas9/. 
 29. Jeffry D. Sander & J. Keith Joung, CRISPR-Cas Systems for Editing, Regulating, and 
Targeting Genomes, 32 NATURE BIOTECH. 347, 349 fig.2b (2014). 
 
  
412 CHICAGO-KENT JOURNAL OF INTELLECTUAL PROPERTY Vol 16:408 
nucleotides of the gRNA.30 When CRISPR finds this region, the gRNA will 
insert itself between the two strands of the DNA and latch onto the 
corresponding DNA sequence.31 This will trigger the Cas9 enzyme to cut the 
DNA, introducing a double stranded break (DSB).32 This break is important 
because DNA needs to be stable.33 At this point, one of two main repair 
pathways can be used to fix the break.34 The cell can repair the DSB on its 
own through a process known as “non-homologous end joining” (NHEJ), or 
through a process known as homologous recombination (HR).35 
With NHEJ, the broken ends of the DNA are rapidly joined together.36 
NHEJ, however, is an error-prone repair process that results in the insertion 
or deletion of one or more bases at the site of repair.37 Adding or removing 
a base (i.e. nucleotide) results in a frameshift mutation because it causes a 
shift in the codon reading frame.38 Codons, each consisting of 3 nucleotides, 
code for amino acids.39 Amino Acids are the building blocks of proteins.40 
Frameshift mutations can introduce premature stop codons and result in 
many amino acid changes that prevent the protein from properly 
 
 30. Id.; CRISPR/Cas9 Guide, ADDGENE, https://www.addgene.org/crispr/guide (last visited Jan. 
28, 2017); Jennifer Doudna, Genome Engineering with CRISPR-Cas9: Birth of a Breakthrough 
Technology, IBIOLOGY (Mar. 23, 2015), https://www.ibiology.org/ibiomagazine/jennifer-doudna-
genome-engineering-with-crispr-cas9-birth-of-a-breakthrough-technology.html. See also Jorgensen, 
supra note 24. 
 31. Sander & Joung, supra note 29, at 349 fig.2b; CRISPR/Cas9 Guide, supra note 30; Doudna, 
supra note 30. See also Jorgensen, supra note 24. 
 32. Sander & Joung, supra note 29 at 351, fig.4. 
 33. Doudna, supra note 30; Jorgensen, supra note 24; see also A. J. Davis & D. J. Chen, DNA 
Double Strand Break Repair Via Non-homologous End-joining, 2 TRANS. CANCER RES. 130, 132 
(2013). 
 34. D. Akcay et al., The Past, Present and Future of Gene Correction Therapy, 3 ACTA MEDICA 
51, 54-55 (2014). 
 35. Id. 
 36. Id. at 55. 
 37. Id. at 54-55. 
 38. Id. 
 39. Central Dogma and the Genetic Code, KHANACADEMY, 
https://www.khanacademy.org/science/biology/gene-expression-central-dogma/central-dogma-
transcription/a/the-genetic-code-discovery-and-properties (last visited Jan. 27, 2017). 
 40. Id. 
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functioning.41 Hence, the NHEJ process can be used to inactivate a gene (i.e. 
“knock out” a gene).42 
DSBs can also be repaired through the HR process if an identical 
sequence homology is present in the cell.43 Unlike NHEJ, HR repairs the 
DSB by using an undamaged identical DNA template.44 Researchers can use 
an artificial DNA sequence to trigger HR, and “knock in” or even “knock 
out” genes at target locations.45 This process introduces three components 
into the cell: the gRNA, Cas9, and a piece of DNA (donor DNA).46 When 
the Cas9 enzyme makes a DSB in the DNA, the cell will look for a related 
DNA sequence to use as a template to repair the DNA.47 Humans inherit two 
sets of chromosomes from each parent.48 When a DSB occurs in diploid 
organisms such as humans, the sister chromatid is usually used as a template 
in the HR process to repair the DNA.49 However, researchers can trick the 
cell into using a foreign donor DNA to mend the break.50 In this case, the 
donor DNA is designed such that the specific elements to be added are in the 
middle, and the ends consist of arms (homology arms) that are homologous 
to the corresponding end regions of the DSB. 51  Hence, when the Cas9 
 
 41. What Kinds of Gene Mutations are Possible? G1 10ENETICS HOME REF., 
https://ghr.nlm.nih.gov/primer/mutationsanddisorders/possiblemutations (last visited Feb. 14, 2017); see 
also Abby Dernburg, Lecture 4: Classification of Mutations by Their Effects on the DNA Molecule, 
http://mcb.berkeley.edu/courses/mcb142/lecture%20topics/Dernburg/Lecture6_Chapter8_screenviewin
g.pdf (last visited Dec. 23, 2016). 
 42. What Kinds of Gene Mutations are Possible?, supra note 41. See also Dernburg, supra note 
41. 
 43.  Akcay, supra note 34, at 54. 
 44.  Id. 
 45. Ignazio Maggio & Manuel A. F. V. Goncalves, Genome Editing at the Crossroads of 
Delivery, Specificity, and Fidelity, 33 TRENDS BIOTECH. 280, 280-81 (2015). See also Akcay, supra 
note 34, at 54. 
 46. Id. at 280; Generating a Knock-out Using CRISPR/Cas9, ADDGENE, 
https://www.addgene.org/crispr/guide/#ko-generation (last visited Feb. 14, 2017). 
 47. Martin Jinek et al., RNA-programmed Genome Editing in Human Cells, 2 eLIFE e00471 
(2013), http://dx.doi.org/10.7554/eLife.00471. See also Jorgensen, supra note 24; Jennifer Doudna, 
How CRISPR Lets Us Edit Our DNA, TED (Sept. 2015), 
https://www.ted.com/talks/jennifer_doudna_we_can_now_edit_our_dna_but_let_s_do_it_wisely. 
 48. April Klazema, Haploid vs Diploid Cells: How to Know the Difference, UDEMYBLOG (June 
13, 2014), https://blog.udemy.com/haploid-vs-diploid. 
 49. Tamara Goldfarb & Michael Lichten, Frequent and Efficient Use of the Sister Chromatid for 
DNA Double-Strand Break Repair during Budding Yeast Meiosis, 8 PLOS BIO. e1000520 (2010), 
10.1371/journal.pbio.1000520; see also Jorgensen, supra note 24; Doudna, supra note 30. 
 50. The Basics of CRISPR/Cas9, GENOME EDITING UIC, 
https://sites.google.com/site/genomeedits/basics (last visited Feb 15, 2017); see also Jorgensen, supra 
note 24; Doudna, supra note 30. 
 51. Akcay, supra note 34 at 54fig1; s. ee also Chari Cortez, CRISPR 101: Homology Directed 
Repair, ADDGENE BLOG, http://blog.addgene.org/crispr-101-homology-directed-repair (last visited Feb 
15, 2017). 
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enzyme makes the cut, the cell proceeds to incorporate it into the gap through 
HR instead of NHEJ.52 
This idea of using donor DNA to introduce desired genes into our cells 
opens endless possibilities because HR is considered to be a more accurate 
and precise repair pathway than NHEJ. 53  With HR, researchers are 
theoretically able to turn on and off genes at targeted locations without 
disrupting untargeted parts of the genome.54 There are currently over 10,000 
human diseases caused by a mutation in a single gene. 55  Single gene 
disorders, also known as monogenic diseases, include Huntington’s disease, 
Cystic Fibrosis, Sickle cell anemia, Tay sachs disease, and Thalassaemia.56 
Beyond single gene disorders, researchers believe CRISPR will one day be 
used to cure complicated genetic disorders, and even prevent disorders such 
as Down syndrome before a child is born.57 
B. CRISPR, ZFNs, and TALENs 
CRISPR is the latest genome editing tool to enter the biotech field, but 
it is not the only tool that can make DSBs. 58  The CRISPR system, as 
previously mentioned, relies on a programmable RNA-guided nuclease to 
target specific DNA sequences.59 Currently, researchers are using the Cas9 
enzyme to cleave DNA.60 However, it is only a matter of time before a more 
efficient RNA-guided nuclease is discovered. 61  For instance, the Cpf1 
enzyme was recently found to be easier to use and produce less errors in 
comparison to the Cas9 enzyme.62 
 
 52. Id. 
 53. Cortez, supra note 51. 
 54. Jelor Gallego, Modified CRISPR Can Now Turn Gene Expression On and Off, FUTURISM 
(Mar. 17, 2016), https://futurism.com/modified-crispr-can-now-turn-gene-expression-off. 
 55. Genes and Human Disease, WORLD HEALTH ORG., 
http://www.who.int/genomics/public/geneticdiseases/en/index2.html (last visited Dec. 23, 2016). 
 56. Id. 
 57. CRISPR . . . Changing the World, GENOME COMPILER (Nov. 12, 2013), 
http://www.genomecompiler.com/crispr-changing-the-world. 
 58. Akcay, supra note 34, at 60-61. 
 59. Jinek, supra note 13, at 816. 
 60. Id. 
 61. Mike Williams, Rice Lab Offers New Strategies, Tools for Genome Editing, RICE (Feb. 8, 
2016), http://news.rice.edu/2016/02/08/rice-lab-offers-new-strategies-tools-for-genome-editing. 
 62. Bernd Zetsche et al., Cpfl is a Single RNA-guided Endonuclease of a Class 2 CRISPR-Cas 
System, 163 CELL 759 (2015). 
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Researchers have been, and are still using other technologies that utilize 
programmable nucleases to modify eukaryotic genomes. 63  Technologies 
based on artificial enzymes known as zinc finger nucleases (ZFNs) and 
transcription activator-like effector nucleases (TALENs) have also been 
used by researchers for years.64 Researchers have been using technologies 
based on ZFNs and TALENs to study how our genes work in mice, rats, and 
in various cell lines similar to those in humans.65 ZFNs, which have been in 
use since the mid-1990s, was tested for the first time by U.S. researchers in 
2014 on 12 HIV patients.66 ZFN-based technology was used to modify the 
gene encoding CCR5, the “Trojan horse” used by HIV to infect the human 
immune system.67 Similarly, in 2015, TALEN-based technology was used 
for the first time in a human by British researchers.68 It was successfully used 
to treat a baby diagnosed with acute lymphoblastic leukemia.69 Technologies 
utilizing ZFNs, TALENs, and CRISPR largely make up the genome editing 
market today.70 It is currently a $2.84 billion-dollar industry that is projected 
to nearly double in revenue by 2021.71 
C. Why is CRISPR Special? 
The two major repair pathways NHEJ and HR are not new. 72 
Researchers have been studying these pathways for years by implementing 
them in fruit flies and lab animals.73 Gene editing tools that make DSBs are 
not new. 74  Moreover, tools utilizing programmable nucleases to target 
specific DNA sequences are not new.75 Technologies based on ZFNs and 
 
 63. Akcay, supra note 34, at 60-61. 
 64. Akcay, supra note 34, at 55-57. 
 65. Id. 
 66. Sara Reardon, Gene-editing Method Tackles HIV in First Clinical Test, NATURE (Mar. 5, 
2014), http://www.nature.com/news/gene-editing-method-tackles-hiv-in-first-clinical-test-1.14813. 
 67. Id. 
 68. Sara Reardon, Leukemia Success Heralds Wave of Gene-editing Therapies, NATURE (Nov. 
10, 2014), http://www.nature.com/news/leukaemia-success-heralds-wave-of-gene-editing-therapies-
1.18737. 
 69. Id. 
 70. RnR Market Research, Genome Editing Market (CRISPR, TALEN, ZFN) to See 14.3% CAGR 
to 2021, PR NEWSWIRE (Oct. 13, 2016), http://www.prnewswire.com/news-releases/genome-editing-
market-crispr-talen-zfn-to-see-143-cagr-to-2021-596898941.html. 
 71. Id. 
 72. Akcay, supra note 34, at 53-55. 
 73. Id. at 56. 
 74. Id. at 53. 
 75. Id. at 60-61. 
 
  
416 CHICAGO-KENT JOURNAL OF INTELLECTUAL PROPERTY Vol 16:408 
TALENs are still being used even with the rise of CRISPR. 76  Further, 
genome editing technology has successfully been used in humans to treat 
genetic conditions.77 At this point, it is only logical to ask why CRISPR is 
considered to be “revolution”78 if it is not doing something new. 
First, CRISPR is relatively simpler to use in comparison to the other 
options.79 ZFN and TALEN based technology rely on proteins for DNA 
recognition.80 This means that every time a researcher wants to target a 
different segment of the DNA, a new protein needs to be engineered.81 
Unlike ZFNs and TALENs, CRISPR relies on RNA and complementary 
base pairing for DNA recognition.82 A researcher using CRISPR need only 
synthesize a 20-nucleotide strand of gRNA, which is simple compared to the 
amount of work that goes into ZFN and TALEN based technology.83 ZFN 
and TALEN are difficult to engineer, require sophisticated protein 
engineering, and involve a certain degree of trial and error (depending on 
how complex the sequence is). 84  Today, do-it-yourself (DIY) bacterial 
CRISPR kits are available for sale on the market.85 These DIY kits give 
people outside of the scientific community a chance to use CRISPR to 
modify genes of a strain of bacteria.86 
Second, CRISPR is a much cheaper alternative to ZFNs and TALENs 
due to its simplicity.87 ZFN enzymes cost anywhere from $4,000 to $7,000 a 
piece.88 TALEN plasmids, on the other hand, cost only $65 a piece, with the 
 
 76. Id. 
 77. Reardon, supra note 68. 
 78. Jennifer Doudna, Genome-editing Revolution: My Whirlwind Year with CRISPR, NATURE 
(Dec. 22, 2015), http://www.nature.com/news/genome-editing-revolution-my-whirlwind-year-with-
crispr-1.19063; Brad Plumer & Janvier Zarracina, Guide to CRISPR Gene Editing Revolution, GENETIC 
LITERACY PROJECT (Jan. 3, 2017), https://www.geneticliteracyproject.org/2017/01/03/guide-crispr-
gene-editing-revolution; Bruce Booth, CRISPR/Cas9 Already is a Revolution in Molecular Biology, 
MEDCITYNEWS (June 9, 2016), http://medcitynews.com/2016/06/crispr-cas9-revolution. 
 79. Paul BG van Erp et al., The History and Market Impact of CRISPR RNA-guided nucleases, 12 
CURRENT OPINION IN VIROLOGY, 85, 85-90 (2015). 
 80. Id. at 86. 
 81. Id. 
 82. Id. 
 83. Id. 
 84. Id. 
 85. Andrew Tarantola, I Played God with the Odin’s DIY CRISPR Kit, ENGADGET (June 30, 
2016), https://www.engadget.com/2016/06/30/i-played-god-with-the-odins-diy-crispr-kit. 
 86. Id. 
 87. van Erp et al., supra note 79, at 87. 
 88. Brian Wang, Disruptive CRISPR Gene Therapy is 150 Times Cheaper Than Zinc Fingers and 
CRISPR is Faster and More Precise, NEXT BIG FUTURE (June 9, 2015), 
http://www.nextbigfuture.com/2015/06/disruptive-crispr-gene-therapy-is-150.html; see Heidi Ledford, 
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popular Golden Gate TALEN Kit priced at $425.89 For research labs across 
the world, purchasing just one customized mouse or rat model could cost up 
to $20,000.90 CRISPR on the other hand, can cost as little as $30.91 This is 
because researchers generally only need to purchase the RNA segment.92 
CRISPR gives more labs the ability to design CRISPR systems on their own 
because it does not require complex engineering like ZFNs and TALENs 
do.93 
Third, CRISPR is much more efficient than ZFNs and TALENs. 94 
Efficiency rates for CRISPR in eukaryotic cells was higher than the rates 
reported for ZFNs and TALENs.95 Unlike ZFNs and TALENs, CRISPR 
allows researchers to modify several genes at once by introducing multiple 
gRNAs.96 Before CRISPR, it could take anywhere from 6 to 12 or more 
months to genetically engineer mice to carry mutations in several genes.97 
Today, labs using CRISPR can implement the same process and generate the 
same results within one month.98 CRISPR has also changed the way whole 
genomes are screened.99 One research lab used CRISPR with nearly 65,000 
different gRNAs to target 18,000 genes.100 Because of its efficiency, cost, 
and ease of use, CRISPR has changed the way scientific research is 
conducted.101 It is predicted that every research lab in the future will be using 
CRISPR.102 
 
CRISPR, the Disruptor, NATURE (June 3, 2015), http://www.nature.com/news/crispr-the-disruptor-
1.17673. 
 89. Wang, supra note 88. 
 90. Jon Cohen, ‘Any Idiot Can Do It.’ Genome Editor CRISPR Could Put Mutant Mice in 
Everyone’s Reach, SCI. MAG. (Nov. 3, 2016, 10:00 AM), 
http://www.sciencemag.org/news/2016/11/any-idiot-can-do-it-genome-editor-crispr-could-put-mutant-
mice-everyones-reach. 
 91. Wang, supra note 88. 
 92. Id. 
 93. Id. 
 94. Monya Baker, Gene Editing at CRISPR Speed, 32 NATURE BIOTECH. 309, 309-12 (2014). 
 95. Id. 
 96. Haoyi Wang et al., One-Step Generation of Mice Carrying Mutations in Multiple Genes by 
CRISPR/Cas-mediated Genome Engineering, 153 CELL 910, 910-18 (2013). 
 97. Id. at 914. 
 98. Id. 
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CRISPR however, is not perfect. 103  It is known in the scientific 
community to have problems with cutting DNA at off-target sites.104 One 
researcher found as many as five mismatches when using CRISPR to cut 
specific target locations. 105  Additionally, using CRISPR-induced HR to 
integrate donor DNA has not been a simple feat.106 Despite the attachment 
of homology arms at either side of the donor DNA, most cells usually repair 
the DSB on its own through the NHEJ process.107 Some cells repair through 
HR, by using the other chromatid as a template instead of the donor DNA.108 
Hence, inducing HR in these types of cell lines can be difficult. 109 
Researchers are trying to find ways to use CRISPR-induced HR to 
successfully manipulate target cells. 110  Despite the numerous scientific 
articles published on CRISPR, there is still so much researchers do not know 
about CRISPR.111 Researchers will most likely begin their projects by using 
CRISPR in order to screen target sequences because of the previously- 
mentioned reasons.112 However, after screening, researchers will most likely 
utilize TALENs or ZFNs to build their projects. 113  In comparison to 
CRISPR, TALENs and ZFNs not only have better specificity, but also have 
the capacity to recognize longer DNA sequences.114 
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D. CRISPR: Naturally-Occurring vs. Modified CRISPR Systems 
CRISPR, that is the functions of CRISPR, is not new to the scientific 
community.115 CRISPR is a naturally-occurring adaptive immune system of 
select bacteria and archaea.116 CRISPR was initially discovered in 1987 by 
researchers who were studying the bacteria E.coli.117 It was not until 2007 
when scientists were able to prove the function of CRISPR by experimenting 
on S. thermophilus, a bacterial strain used to convert milk into yogurt.118 
There are actually three types of CRISPR systems that have been identified, 
of which the type II system is the most studied.119 The type II CRISPR 
system, the simplest of the three systems, is the basis for the CRISPR 
genome editing tool used by researchers today.120 
In bacterium such as Escherichia coli, the type II CRISPR system 
includes CRISPR arrays of short palindromic repeats known as CRISPR 
repeats.121 These CRISPR repeats are separated by spacers, which contain 
unique sequences known as protospacer sequences. 122  Each time the 
bacterium is invaded by a foreign DNA, the type II CRISPR system 
incorporates fragments of the invading DNA into these spacers.123 Hence, 
the CRISPR array grows with every new protospacer sequence that is 
inserted.124 The CRISPR arrays is transcribed into a precursor CRISPR RNA 
known as pre-crRNA. 125  The pre-crRNA is processed into mature short 
CRISPR RNAs (crRNAs).126 Each crRNA has “protospacer” regions, which 
contain complementary sequences that match to a specific sequence in the 
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virus DNA.127 Each crRNA hybridizes with an additional RNA known as a 
trans-activating CRISPR RNA (tracrRNA). 128  These 2 types of RNA 
(crRNA and tracrRNA) then form a complex with a Cas9 nuclease.129 This 
complex actively searches the cell for DNA that matches its protospacer 
sequences.130 Therefore, when the same virus attacks again, the complex is 
able to use the crRNA and tracrRNA to recognize the virus, and latch onto a 
specific site of the invading viral DNA.131 After the matching protospacer 
sequence of the complex binds with the corresponding target site of the 
DNA, Cas9 will disable the virus by cutting the viral DNA.132 The type II 
CRISPR system not only allows the bacterium to remember, record, and 
deactivate its foreign invaders, but also allows it to pass all its stored 
information onto the next generation.133 
The CRISPR system is the adaptive and inheritable immune system of 
certain bacteria and archaea, which are prokaryotes. 134  Prokaryotes are 
simple single-celled organisms that lack a nucleus.135 Instead, prokaryotic 
cells have DNA in the form of a single circular chromosome.136 The CRISPR 
system does not exist naturally in eukaryotic cells.137 Animals and plants are 
eukaryotes.138 Eukaryotic cells have many features such as membrane-bound 
organelles, which are not found in prokaryotic cells.139 However, the most 
important distinction between prokaryotic and eukaryotic cells is that 
eukaryotic cells have a membrane-bound nucleus, which stores the cell’s 
genetic information.140 The genetic information of eukaryotic cells, DNA, is 
organized in chromosomes, of which humans have 46.141 
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In 2012, researchers successfully adapted the type II CRISPR system to 
eukaryotic cells.142 Although the basic function of the naturally-occurring 
type II CRISPR system is mirrored in the engineered CRISPR system, there 
is a notable distinction between the two.143 As previously mentioned, the 
naturally-occurring CRISPR system involves a dual-RNA structure, which 
consists of crRNA and tracrRNA. 144  Researchers from the Doudna and 
Charpentier labs of the University of California, Berkeley (“UCB”) modified 
the CRISPR system so that Cas9 can be used with a single RNA structure 
instead of the dual-RNA structure found in nature.145 A single RNA-guided 
Cas9 complex would allow researchers to program a single RNA to target 
and cut specific sites in the human DNA.146 To create a single RNA structure, 
UCB scientists connected the tracrRNA and crRNA together to create a 
tracrRNA-crRNA chimera. 147  The majority of the engineered CRISPR 
systems today utilize a guide RNA (“gRNA”) that is a chimeric RNA— a 
fusion between a CRNA and part of the tracrRNA.148 
The CRISPR genome editing technology has been used to produce 
some of the most exciting advancements for geneticists in recent years.149 
The potential uses of CRISPR for the advancement of human health is both 
exciting and daunting. 150  The financial stake in this technology is 
enormous.151 Numerous life science companies are offering CRISPR-related 
products.152 CRISPR’s potential for the growth of the therapeutics market 
has also attracted much interest from investors.153 All this excitement in the 
scientific community however, cannot escape the concern surrounding the 
intellectual property (IP) of the CRISPR technology.154 
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II. CRISPR: RELEVANT §101 CASE LAW 
CRISPR has been the subject of an intense patent dispute between Feng 
Zhang of the Broad Institute and MIT (“Broad”) and Jennifer Doudna of the 
University of California, Berkeley (“UCB”) as to who invented the 
technology first.155 There is also another ownership dispute between Broad 
and Rockefeller University as to who the inventors are of several other 
CRISPR patents. 156  The United States Patent and Trademark Office 
(“USPTO”) has issued 28 patents on the CRISPR technology as of 2016.157 
Outside of the U.S., there is a patent dispute over Zhang’s European CRISPR 
patents.158 These aggressive ownership disputes illustrate the role patents 
have in not only protecting an inventor’s work, but also in commercializing 
technology. 
The inventorship disputes surrounding CRISPR raise other patent-
related concerns such as patent validity.159 Because the USPTO has issued 
patents as to CRISPR, it is hypothesized that invalidity disputes as to several 
CRISPR patents will find their way to federal court. CRISPR has garnered a 
lot of interest by scientists, research institutions, and companies—many who 
would clearly benefit from using the technology unencumbered. Invalidity 
disputes concerning the CRISPR patents will most likely be raised under 35 
U.S.C. §102 (“§102”) for lack of novelty or under 35 U.S.C. §103 (“§103”) 
for obviousness. 160  However, this paper will only evaluate the CRISPR 
technology under a hypothetical 35 U.S.C. §101 dispute challenging patent-
eligible subject matter. 
Currently, there is no dispute in federal court challenging the eligibility 
of the CRISPR patents under 35 U.S.C. §101 (hereinafter “§101”). However, 
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recent Supreme Court decisions on §101 have affected the landscape for life 
science patents. 161  By evaluating the CRISPR technology under a 
hypothetical §101 dispute in federal court, this paper intends illustrate how 
the modern §101 framework is applied to life science inventions. 
A. Patents: The Basics 
A patent is a property right the government grants to an inventor for a 
limited period of time—generally, 20 years from the effective filing date of 
the patent application.162 A patent does not grant an inventor the exclusive 
right to make, use, offer for sale, sell, or import the invention.163 Rather, a 
patent grants an inventor the right to exclude others from “making, using, 
offering for sale, or selling” the invention in the U.S. or “importing” the 
invention into the country.164 A patent’s “claims” establish the scope of the 
invention, and define the exclusive right granted to the inventor.165 Hence, 
when a patent dispute is in court because of issues such as invalidity or 
infringement, it is the claims that are litigated—the claims are at stake.166 
The power to grant patents is found in the United States Constitution in 
Art. I, Sec. 8, Clause 8, also known as the Intellectual Property Clause. This 
clause grants Congress the power “to promote the progress of science and 
useful arts, by securing for limited times to authors and inventors the 
exclusive right to their respective writings and discoveries.”167 Pursuant to 
this authority, Congress enacted the U.S. Patent Act (“Patent Act”).168 The 
Patent Act, which is found in Title 35 of the United States Code, authorizes 
the USPTO to establish patent rules not inconsistent with the law.169 The 
USPTO examines patent applications and issues patents.170 
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The 5 primary requirements for patentability are as follows: patentable 
subject matter, utility, novelty, non-obviousness, and enablement.171 These 
requirements are all found in 35 U.S.C. §§101, 102, 103, and 112. After a 
patent has been issued, its validity can be challenged (on any of the grounds 
previously mentioned) in special proceedings at the USPTO or in federal 
court.172 It is worth briefly mentioning that there are two different standards 
that govern patent claims. 173  Prior to issuance, the claims in a patent 
application are examined by the USPTO under a broadest reasonable 
interpretation (BRI) standard. 174  In contrast, patent claims at dispute in 
federal court are construed in accordance to a plain meaning standard.175 
B. Subject Matter Eligibility Under 35 U.S.C. §101 
35 U.S.C. §101 (“§101”) states that anyone who “invents or discovers 
any new and useful process, machine, manufacture, or composition of 
matter, or any new and useful improvement thereof, may obtain a patent 
therefor, subject to the conditions and requirements of this title.”176 Hence, 
only inventions that fall within the patent eligible categories: “process, 
machine, manufacture, or composition of matter” are eligible for patent 
protection.177 The Supreme Court, traditionally, has interpreted §101 to also 
include “implicit exception[s]” to 3 broad principles: laws of nature, natural 
phenomena, and abstract idea. 178  Inventions directed to one of these 
judicially recognized exceptions (referred to as “judicial exceptions”) have 
long been held by courts as patent ineligible.179 The discovery of a law of 
nature, physical phenomena, or abstract idea itself is not patentable because 
these are “manifestations of nature which are free to all men and reversed 
exclusively to none.”180 Hence, the discovery of a new mineral or plant found 
 
 171. Patent, LEGAL INFO. INST., https://www.law.cornell.edu/wex/patent (last visited on Dec. 23, 
2016). 
 172. MPEP §1216 (“Judicial Review”) (9th ed., rev. 7 Nov. 2015) (hereinafter “MPEP”). 
 173. MPEP §2111 (“Claim Interpretation; Broadest Reasonable Interpretation”). 
 174. Id.; see also Fanelli Haag, Practical Implications of the Two Claim Construction Standards in 
the Post-AIA World, LEXOLOGY, July 16, 2015, 
http://www.lexology.com/library/detail.aspx?g=260f7965-7f9c-463d-859f-7d5c6b6a7575. 
 175. Id. (this is also known as the Phillips standard.). 
 176. 35 U.S.C. § 101 (2012). 
 177. Id. 
 178. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013) 
(quoting Mayo Collaborative Servs. v. Prometheus Labs, Inc., 566 U.S. 66, 70-71 (2012)). 
 179. Id. 
 180. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (quoting Funk Brothers Seed. Co. v. Kalo 
Inoculant Co., 333 U.S. 127, 130 (1948)). 
 
  
2017 THE PATENTABILITY OF THE CRISPR-CAS9 GENOME EDITING TOOL 425 
in nature is not patentable.181 This also explains why celebrated discoveries 
such as Einstein’s formula E=mc2 and Newton’s law of gravity were not 
patentable.182 
The patent system exists to award inventive activity and encourage 
innovation.183 Hence, patents are not meant to give a select few the power to 
monopolize knowledge belonging in the public domain. On the other hand, 
too narrow of an interpretation of §101 could impede innovation. 184  In 
recognizing the dangers of interpreting the judicial exceptions too broadly, 
the Supreme Court has long acknowledged that “all inventions at some level 
embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, 
or abstract ideas.” 185  Thus, the Supreme Court has held that the mere 
recitation of a judicial exception does not make a claim ineligible for 
patenting.186 Rather, it is the application of the judicial exception that needs 
to be examined.187 
C. Pre-Alice: Relevant Supreme Court Decisions 
Before applying the modern framework to a hypothetical §101 subject 
matter eligibility CRISPR dispute, it is helpful to review several relevant 
Supreme Court decisions. Prior to Alice Corp. Pty. Ltd. v. CLS Bank Int’l,188 
(hereinafter “Alice”) the Supreme Court had issued several subject matter 
eligibility decisions pertinent to the life sciences field. In Diamond v. 
Chakrabarty (hereinafter “Chakrabarty”), the Supreme Court held that 
living organisms are patentable subject matter under §101. 189  In 
Chakrabarty, a super oil-eating bacterium was at issue.190 Four strains of oil-
eating bacteria that exist in nature, each possess the ability to digest different 
components of the oil.191 These bacteria have plasmids, which are rings of 
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DNA that code for the proteins that eat the oil.192 Dr. Chakrabarty combined 
the four plasmids into a single bacterium, effectively creating a new species 
of bacteria.193 In a 5-4 decision, the Supreme Court held that a live, human-
made microorganism was patentable subject matter under §101 because the 
oil-eating property of the genetically modified bacterium was not possessed 
by any naturally occurring bacteria.194 
The Chakrabarty decision laid the foundation for allowing the patenting 
of genetically modified living organisms such as transgenic mice.195 It is 
important to note that patent claims directed to human organisms, such as 
embryos and fetuses, have never been patent eligible subject matter.196 In 
Mayo Collaborative Servs. v. Prometheus Labs., Inc (hereinafter “Mayo”), 
the Supreme Court laid out the inventive concept requirement seen in the 
second step of the Alice framework.197 The invention at issue in Mayo was a 
personalized medicine dosing process. 198  Researchers discovered natural 
correlations between specific metabolite levels in the body and a dosage 
range for the drug thiopurine.199 The invention identified methods reciting 
steps such as “administering” a drug to a patient, “determining” the level of 
metabolite in the patient, and adjusting the dosage based on the correlation 
discovered by the researchers.200 In a 9-0 decision, the Supreme Court held 
that the dosing process was not patentable subject matter under §101 because 
the correlation claimed was a law of nature.201 Further, the Court held that 
the additional steps, “when viewed as a whole,” were not enough to 
transform the judicial exception into a patentable application of it.202 
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In Ass’n for Molecular Pathology v. Myriad Genetics, Inc. (hereinafter 
“Myriad”), the Supreme Court held that a “naturally-occurring DNA 
segment” is not patent eligible merely because its covalent bonds were 
severed in order to isolate the DNA segment.203 Rather, an isolated segment 
of naturally occurring DNA is a patent ineligible product of nature.204 The 
Court also held that complementary DNA (cDNA) is patent eligible subject 
matter. 205  The Court reasoned that cDNA, a synthetic version of DNA 
created from mRNA, “contains only the exons that occur in DNA, omitting 
the intervening introns.”206 Exons are the expressed sequences of DNA that 
code for protein whereas intron are non-expressing sequences of DNA that 
do not code.207 The rationale behind the Myriad decision is based on the fact 
that DNA stores genetic information. 208  Although isolated DNA and 
naturally occurring DNA have chemical differences due to the breaking of 
the covalent bonds, the genetic information stored in the isolated DNA is the 
same when compared to its naturally occurring state.209 The breaking of 
covalent bonds “does not change the information-transmitting quality.”210 
However, cDNA is created in a lab by removing introns from naturally 
occurring genomic DNA through known lab procedures.211 Hence, because 
cDNA is not naturally occurring in its natural environment (human cells), it 
is patent eligible.212 This decision has sparked much debate in the scientific 
community as many scientists believe that the difference between cDNA and 
naturally occurring genomic DNA (gDNA) are trivial.213 
Lastly, it is worth pointing out In re Roslin Inst. (Edinburgh), 
hereinafter “Roslin.”214 This decision from the U.S. Court of Appeals for the 
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Federal Circuit (hereinafter “Federal Circuit”) was issued one month before 
the Supreme Court’s Alice decision.215 In Roslin, the Federal Circuit held that 
Dolly the cloned sheep, effectively any genetic clone, is not patentable 
subject matter under §101.216 Dolly was cloned from an adult somatic cell.217 
The method of cloning mammals by using somatic cells was patented, and 
not at issue in this case.218 At issue, rather, was whether the products of the 
cloning method could be patented.219 The Roslin court compared the claimed 
clones to the isolated DNA in Myriad and reasoned that no genetic 
information (of the clones) was created or altered.220 The court also pointed 
out that “the genetic structure of the DNA used to make [the] clones” was 
not created or altered in any way. 221  In rejecting the patent claims, the 
Federal Circuit reasoned that Dolly, the claimed subject matter, did not 
possess markedly different characteristics from her donor parent.222 Dolly 
was an “exact genetic replica” of her donor parent, and therefore patent 
ineligible.223 
D. The Modern Approach on §101 Analysis: Alice 
At the outset of every §101 subject matter eligibility inquiry, it is 
necessary to ask if the invention falls within one of the 4 patent-eligible 
categories.224 If the invention does not have any claims directed to either a 
process, machine, manufacture, or composition of matter, the inquiry goes 
no further.225 The invention is not eligible for patent protection.226 In Alice, 
the Supreme Court articulated a 2-part framework for distinguishing patents 
that claim a patent-ineligible judicial exception from those that claim a 
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patent-eligible application of the exceptions.227 The Alice decision focused 
on the judicial exception of abstract ideas in the context of computer-related 
inventions.228 However, its framework was derived in large part from Mayo, 
where the Supreme Court held methods of administering a drug based on 
specific levels of a metabolite to be patent ineligible.229 
The first step of the Alice framework is to determine “whether the 
claims at issue are directed to a patent-ineligible concept.”230  It is well 
established that products of nature, as opposed to those of human 
intervention, fall within the judicial exceptions.231 Therefore, inventions that 
encompass a product derived from natural sources (known as “nature-based 
products”) are analyzed more closely under this first step.232 Nature-based 
products, like CRISPR, must possess “markedly different characteristics” 
from any found in nature in order to be patent eligible.233 The nature-based 
product limitation is compared to its naturally-occurring counterpart found 
in its natural state.234 Types of characteristics to consider when determining 
“markedly different characteristics” include, but are not limited to the 
following: biological functions or activities, chemical and physical 
properties, phenotype, and structure and form.235 If the nature-based product 
limitation has markedly different characteristics, the patent claim at issue is 
patent eligible under §101.236 The eligibility inquiry stops here.237 
If, however, the answer is no (there are no markedly different 
characteristics), the eligibility inquiry continues onto the second step.238 The 
second step of the Alice framework is to determine whether the claim recites 
any “additional elements [that] ‘transform the nature of the claim’ into a 
patent-eligible application.” 239  There needs to be an inventive concept 
 
 227. See Alice Corp. Pty. Ltd., 134 S. Ct. at 2355; see 2014 Interim Eligibility Guidance Quick 
Reference Sheet, supra note 225. 
 228. Alice Corp. Pty. Ltd., 134 S. Ct. at 2357. 
 229. Mayo Collaborative Servs., 566 U.S. at 71-72. 
 230. Alice Corp. Pty. Ltd., 134 S. Ct. at 2355. 
 231. 2014 Interim Eligibility Guidance Quick Reference Sheet, supra note 225. 
 232. Id.; Alice Corp. Pty. Ltd., 134 S. Ct. at 2355. 
 233. 2014 Interim Eligibility Guidance Quick Reference Sheet, supra note 225. 
 234. Id. 
 235. Analyzing Nature-based Products Slides, USPTO Training Materials on Subject Matter 
Eligibility, 1-39, 9 (Feb. 2015), available at 
https://www.uspto.gov/sites/default/files/documents/101%20JE%20training%20Nature-
Based%20Products%20Module.pdf 
 236. 2014 Interim Eligibility Guidance Quick Reference Sheet, supra note 225. 
 237. Id. 
 238. Id. 
 239. Alice Corp. Pty. Ltd., 134 S. Ct. at 2357 (quoting Mayo Collaborative Servs., 566 U.S. at 78). 
 
  
430 CHICAGO-KENT JOURNAL OF INTELLECTUAL PROPERTY Vol 16:408 
sufficient to guarantee that the claim “amounts to significantly more” than 
the judicial exception itself.240 In determining if there is an inventive concept, 
all the claim elements, must be considered “both individually and in 
combination[.]”241 If there is an inventive concept, the claims at issue are 
patent eligible under §101.242 If the patent claims instead recite additional 
elements that involve “well-understood, routine, conventional activity,” the 
claims are patent ineligible.243 
E. Post-Alice Decisions: Applying Alice 
Since the Supreme Court’s Alice decision in 2014, the Federal Circuit 
has issued several §101 subject matter eligibility decisions, of which two are 
relevant to the life sciences field.244 These decisions provide some guidance 
on how the Alice framework is being applied to life science inventions in 
federal court. First, the Federal Circuit held in Rapid Litig. Mgmt. v. 
CellzDirect, Inc. (“CellzDirect”) that an improved process of cryopreserving 
hepatocyte cells was patent eligible under §101.245 Hepatocytes, a type of 
liver cell, are preserved for future use in a process known as 
cryopreservation.246 Here the inventors discovered that “some fraction of 
hepatocytes are capable of surviving multiple freeze-thaw cycles.”247 Instead 
of using frozen cells once, scientists could refreeze the cells and use them 
again.248 The patent claimed an improved process which recited steps such 
as “subjecting” previously frozen cells to a known technique to separate 
viable and non-viable cells, “recovering” the viable cells, and “refreezing” 
these cells. 249  The claims specified that this preparation could be used 
immediately after thawing, exhibiting 70% viability.250 
In applying the first step of the Alice framework, the Federal Circuit 
held that the claims were not directed to a patent ineligible judicial 
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exception. 251  The court reasoned that the inventors did not patent their 
natural discovery, but instead used it “to create a new and improved way of 
preserving hepatocyte cells for later use.”252 The Federal Circuit emphasized 
that in asking if a claim is “directed to” a judicial exception, “merely 
identify[ing] a patent-ineligible concept” “is not enough.”253 Rather, “the end 
result of the process,” as a whole must be an ineligible judicial exception.254 
The end result here was more than an “observation or detection of the ability 
of hepatocytes to survive multiple freeze-thaw cycles”—it was an improved 
process “of producing a desired preparation.”255 Because the patent claims 
were not directed to a judicial exception, the eligibility inquiry did not move 
on to the second step.256 
Second, the Supreme Court denied a petition for writ of certiorari in 
Sequenom, Inc. v. Ariosa Diagnostics, Inc. 257  (hereinafter “Sequenom”), 
leaving the Federal Circuit decision in place.258 In Sequenom, the Federal 
Circuit held a fetal DNA diagnostic method to be patent ineligible subject 
matter under §101.259 Scientists discovered the presence of cell-free fetal 
DNA (cffDNA) in the bloodstream of pregnant women.260 The idea was that 
fetal DNA could be accessed separately from the maternal DNA by linking 
it to the paternal DNA portion of the cffDNA.261 This discovery made it 
possible to create a non-invasive prenatal test to screen for genetic defects in 
the fetus. 262  The patent claimed a method, which recited two steps: 
“amplifying” a sample of cffDNA taken from a pregnant woman, and 
“detecting” the paternally-inherited portion of DNA in the cffDNA.263 
In applying the first step of the Alice framework, the Federal Circuit 
held that the claimed method was directed to a patent ineligible natural 
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phenomena.264 In applying the second step, the court held that the method 
did not recite an inventive concept that transformed the judicial exception 
(presence of cffDNA in maternal bloodstream) into a patent eligible 
application of the exception.265 The court compared the invention to Mayo 
and reasoned that the additional “amplifying” and “detecting” steps were 
“well-understood, routine, and conventional activity” at the time the patent 
application was filed.266 This decision was not unexpected.267 However, it 
was not well-received by the life sciences field,268 especially after the court 
acknowledged that the discovery “may have been a significant contribution 
to the medical field.”269 Many in the life sciences field believe that under the 
Intellectual Property Clause and patent laws, new and useful discoveries 
should be eligible for patent protection.270 
III. CRISPR: HYPOTHETICAL §101 PATENT INVALIDITY DISPUTE 
As previously mentioned, there are 28 U.S. patents on the CRISPR 
technology as of February 2016.271 These patents all claim different aspects 
and variations of the CRISPR technology.272 Instead of applying the §101 
framework to each of the patents, it would be in the best interest of this 
paper’s purpose to focus on the patent claims that cover the core CRISPR 
technology. This paper will apply the §101 analysis to the single count in the 
current USPTO patent interference proceeding between Doudna (UCB) and 
Zhang (Broad).273 The one count in dispute is as follows:274 
A method, in a eukaryotic cell, of cleaving or editing a target DNA molecule or 
modulating transcription of at least one gene encoded thereon, the method 
comprising: 
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contacting, in a eukaryotic cell, a target DNA molecule having a target sequence 
with an engineered and/or non-naturally-occurring Type II Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) 
(CRISPR-Cas) system comprising: 
 
a) a DNA-targeting RNA comprising 
i) a targeter-RNA or guide sequence that hybridizes with the target 
sequence, and 
ii) an activator-RNA or tracr sequence that hybridizes with the targeter-
RNA to form a double-stranded RNA duplex of a protein-binding segment, 
and 
b) a Cas9 protein, 
 
wherein the DNA-targeting RNA forms a complex with the Cas9 protein, thereby 
targeting the Cas9 protein to the target DNA molecule, whereby said target DNA 
molecule is cleaved or edited or transcription of at least one gene encoded by the 
target DNA molecule is modulated.275 
A count is a best described as a “hypothetical patent claim” that covers 
the overlapping invention.276 In the CRISPR interference proceeding, a 3-
judge panel compared UCB’s pending patent application (No. 13/842,859) 
to the Broad’s 12 U.S. patents and found that they overlapped as to the one 
count mentioned above.277 At issue is a DNA-editing method.278 The method 
recites one step of “contacting” a target DNA molecule in a eukaryotic cell 
with a Type II CRISPR system.279 The claimed CRISPR system is described 
as essentially having two components: a guide RNA (the “DNA-targeting 
RNA”) made up of a targeter and an activator RNA, and a Cas9 protein.280 
The guide RNA (gRNA) is described as forming a complex with the Cas9 
protein to cut the target DNA molecule.281 
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A. CRISPR: Applying the §101 Alice Framework 
Before applying the Alice framework, the patent claim in dispute needs 
to fall within one of the four subject matter eligible categories. Here, a 
process claim is in dispute. The first step in Alice asks whether the claim at 
issue is directed to a patent-ineligible judicial exception. Per the USPTO 
training materials, process claims are not subject to the markedly different 
characteristics analysis used for nature-based products unless the process 
claim is “drafted in such a way that there is no difference in substance from 
a product claim to a nature-based product.”282 Here, the only method step is 
arguably the “contacting” step. The rest of the claim is directed to a nature-
based product limitation because the type II CRISPR system is a naturally 
occurring phenomena in select prokaryotes. Hence, this CRISPR system 
described in the patent claim needs to be examined under the “markedly 
different characteristics” analysis.283 
The claimed CRISPR system possesses characteristics that are 
markedly different from the naturally-occurring counterpart found in select 
bacteria. Under the analysis, markedly different characteristics based on 
properties such as structure and function need to be identified. First, the 
structure of the “DNA-targeting RNA”284 in the claimed CRISPR system is 
different from the structure found in nature. In the naturally-occurring 
CRISPR system, the “DNA-targeting RNA” 285  is a dual RNA structure 
comprising of crRNA, which is the targeter RNA, and tracrRNA, which is 
the activator RNA. The “DNA-targeting RNA” found in the claimed 
CRISPR system is a single RNA structure. This single RNA structure 
(gRNA), is a fusion of the crRNA and tracrRNA, which is naturally found 
in the CRISPR system of select prokaryotes.286 Researchers implementing 
the type II CRISPR system design gRNA using segments of crRNA and 
tracrRNA.287 However, even though the naturally-occurring components are 
the same, the amount of each component used is different.288 The claimed 
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CRISPR system is used in different eukaryotic cell lines.289 Based on the cell 
line and need, truncated versions of crRNA and tracrRNA can be used.290 
The rationale in Myriad seems to emphasis the importance of structural 
differences over chemical differences in determining whether a nature-based 
product is markedly different from its naturally-occurring counterpart.291 In 
Myriad, the Supreme Court held that “Myriad did not create or alter either 
the genetic information encoded in the BRCA1 and BRCA2 genes or the 
genetic structure of the DNA.”292 Similar to the cDNA of Myriad, which was 
held to be patent eligible because of the removal of naturally present 
introns293 , the fusion of crRNA and tracrRNA here into a single RNA 
structure is a notable structural difference. 
Second, the function of the claimed CRISPR system is different from 
the function of its naturally-occurring counterpart. The CRISPR system of 
bacteria such as Streptococcus pyogenes, acts as an immune system to help 
the bacteria defend against foreign invaders, such as viruses.294 The type II 
CRISPR system incorporates segments of the invading virus DNA into its 
protospacer regions. 295  Further, naturally-occurring CRISPR of some 
bacteria wait until the foreign invader starts replicates before attacking.296 In 
contrast, the claimed CRISPR system is not used as an immune system, but 
as a genome editing tool. Hence its function is different. 
Also, instead of inserting a piece of foreign DNA into its system to 
defend against future attacks, the claimed CRISPR system is inserted into 
eukaryotic cells in order to recognize and cut target DNA sequences. Further, 
the purpose of modifying the dual RNA structure to a single RNA structure 
is to deliver foreign DNA (i.e. specific sequences of DNA) to specific target 
sites in the genome. 297  Programming a single RNA structure to target 
different DNA sequences is a markedly different characteristic consistent 
with the rationale of Myriad and Roslin. In Roslin, the Federal Circuit held 
that the clones did not have “markedly different characteristics from the 
donor animals” because the genetic information of the clones remained 
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unchanged.298 Unlike the clones in Roslin, the genetic information of the 
“DNA-targeting RNA”299 in the claimed CRISPR system is different from 
its naturally-occurring counterpart because each “DNA-targeting RNA”300 
can incorporate different DNA sequences to target a specific sequence in the 
genome. 
A narrow interpretation of recent case law has led some to conclude that 
the claimed CRISPR system does not possess markedly different 
characteristics from its naturally-occurring counterpart.301 In The Failure to 
Preserve CRISPR-Cas9’s Patentability Post Myriad and Alice, Tuttle points 
to the fact that the same Cas9 nuclease, crRNA, and tracrRNA found in 
nature are used in the engineered CRISPR system.302 Further, Tuttle points 
out that in order to cut at target DNA sites, the “DNA-targeting RNA”303 
needs to incorporate a matching sequence that is identical to its naturally-
occurring counterpart.304 He elaborates that if this does not occur, the targeter 
RNA of the “DNA-targeting RNA”305 will not recognize and bind to its 
target DNA sequence.306 Although these are all valid points to be made, the 
Federal Circuit emphasized in the recent CellzDirect decision that the patent 
claim as a whole, that is, “the end result of the process,” needs to be directed 
to a judicial exception in the first Alice step.307 Although the type II CRISPR 
system itself is a natural phenomenon, and the individual components of the 
claimed CRISPR system can be found in nature, the claimed system as a 
whole is not naturally found in prokaryotes or eukaryotes. A court that finds 
the patent claim at issue to not be directed to a patent ineligible judicial 
exception will stop the eligibility inquiry here, and hold that the claim 
covering the CRISPR system is patent eligible subject matter under §101.308 
If a court instead finds that the claimed CRISPR system contains no 
markedly different characteristics from its naturally-occurring counterpart, 
the eligibility inquiry will continue onto the second step under Alice. The 
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second step asks whether the patent claim recites additional elements that 
transform the judicial exception into a patent-eligible application of the 
exception (here, nature-based product).309 In short, under this second step, 
there needs to be an inventive concept.310 If a court did not find the patent 
claim covering the CRISPR system to be patent eligible under the first step 
of Alice, they will most certainly find it to eligible under the second step. 
First the patent claim at issue takes the naturally-occurring type II CRISPR 
system and implements it in a eukaryotic cell. Eukaryotic cells do not 
naturally have a CRISPR system.311 Scientific literature from the Doudna 
(UCB) and Zhang (Broad) labs (as well as earlier scientists) illustrate that 
getting the naturally-found CRISPR system (dual RNA structure) to work in 
eukaryotic cells required human intervention.312 Both the Doudna and Zhang 
publications illustrate the experiments both labs conducted in order to get the 
naturally-occurring CRISPR system (dual RNA structure) and claimed 
CRISPR system (single RNA structure) to properly function in eukaryotic 
cells.313 
Second, scientists connected crRNA and tracrRNA to form a single 
RNA structure to use the claimed CRISPR system as a genome editing tool 
in eukaryotic cells.314 This is similar to the improved process of preserving 
hepatocyte cells in CellzDirect. In CellzDirect, scientists discovered that a 
fraction of frozen hepatocyte cells could be reused again. 315  They 
subsequently patented an application of that discovery—an improved 
method of preserving hepatocytes for later use.316 The Federal Circuit held 
that the scientists did not patent the discovery, but rather “as the first party 
with knowledge of the cells’ ability, they were ‘in an excellent position to 
claim applications of that knowledge.’”317 In the same way, scientists at UCB 
and Broad discovered the function and mechanisms of the type II CRISPR 
system as an adaptive immune system. Instead of patenting this discovery, 
scientists patented applications of this discovery by claiming a genome 
editing tool. Hence, the patent claim at issue is arguably different from the 
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personalized dosing process of Mayo as well as the prenatal genetic 
screening process of Sequenom. Unlike Mayo and Sequenom, the scientists 
here did not stop after discovering the natural phenomena, but worked to 
invent a patent eligible application of the phenomena. Further, the Supreme 
Court emphasized in Alice that the claim elements in the second step of the 
analysis need to be considered “both individually and in combination” as a 
whole.318 Therefore, a court could reasonably conclude that the patent claim 
at issue, when considered as a whole, is a patent-eligible application of a 
judicial exception. Hence, the single count of the interference proceeding 
would be patent eligible subject matter under §101. 
CONCLUSION AND CONSIDERATIONS BEYOND §101 
Under modern patent law, the count (“hypothetical patent claim”)319 
currently at the center of the USPTO interference proceeding would most 
likely be held as patent eligible subject matter. Many people question the 
ethical and moral implications of the patented CRISPR technology. 320 
However, the current §101 framework does not take moral and ethical values 
into consideration. Others like Tuttle are concerned that these patents will 
impede rather than promote downstream research and innovation. 321 
However, the hypothetical §101 invalidity dispute illustrates that under the 
modern Alice framework, the CRISPR-Cas9 technology of the 
Doudna/Zhang interference qualifies as patentable subject matter. 
Preemption concerns can be addressed outside the scope of §101 by raising 
§102 (novelty) and §103 (obviousness) issues. Hence, §101 will likely not 
be an issue in future invalidity challenges. Rather, it is highly probable that 
invalidity challenges as to §103 (obviousness) will be made in federal 
court.322 
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Further, it is important to note that the count only claims a CRISPR 
system that utilizes the Cas9 nuclease. Since the introduction of the CRISPR-
Cas9 technology in 2012, scientists have worked to find a better alternative 
to Cas9.323 In 2015, Zhang discovered Cpf1, a smaller and potentially more 
efficient nuclease than Cas9.324 Researchers from UCB recently discovered 
CasX and CasY—two nucleases which are much smaller and potentially 
more useful than Cas9.325 Further, researchers last year discovered a new 
CRISPR system, C2c2, which potentially allows researchers to edit RNA 
instead of DNA.326 The CRISPR-Cas9 technology allows researchers to edit 
DNA and make permanent changes to a cell’s genome.327 C2c2, on the other 
hand, will allow researchers to target RNA and make temporary changes to 
a cell’s genome.328 Some of these researchers have filed patent applications 
over their improved CRISPR systems. 329  The outcome of the current 
interference proceeding will impact the scope of patent protection available 
to alternative genome editing tools based on the CRISPR-Cas9 
technology.330 Hence, future invalidity disputes over genome editing patents 
will most likely focus on §102 (novelty) and §103 (obviousness) issues 
rather than §101 issues. 
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